![Nosopharm welcomes Jacques Biton and Frédéric Hammel to its supervisory board](https://ala.associates/wp-content/uploads/2022/04/5-novembre-2-pers.png)
![Nosopharm welcomes Jacques Biton and Frédéric Hammel to its supervisory board](https://ala.associates/wp-content/uploads/2022/04/5-novembre-2-pers.png)
![Alaxia joins EU consortium to combat drug-resistant lung infections](https://ala.associates/wp-content/uploads/2022/04/23-octobre.jpg)
Alaxia joins EU consortium to combat drug-resistant lung infections
![Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia](https://ala.associates/wp-content/uploads/2022/04/17-octobre.png)
Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia
![Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia](https://ala.associates/wp-content/uploads/2022/04/12-nov-mex.jpg)
Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia
![Domain Therapeutics reaches two milestones in multi-target research collaboration with Boehringer Ingelheim](https://ala.associates/wp-content/uploads/2022/04/30-sept-mec.png)
Domain Therapeutics reaches two milestones in multi-target research collaboration with Boehringer Ingelheim
![Yposkesi to host roundtable on challenges in gene therapy manufacturing at the Cell and Gene Meeting on the Mesa, October 2-4](https://ala.associates/wp-content/uploads/2022/04/24-septembre.jpg)
Yposkesi to host roundtable on challenges in gene therapy manufacturing at the Cell and Gene Meeting on the Mesa, October 2-4
![Imcyse to present first-in-human phase 1b study results in type 1 diabetes at EASD 2019](https://ala.associates/wp-content/uploads/2022/04/18-sept.png)
Imcyse to present first-in-human phase 1b study results in type 1 diabetes at EASD 2019
![Imcyse to present positive results in EAE model of multiple sclerosis at ECTRIMS 2019](https://ala.associates/wp-content/uploads/2022/04/12-seot.jpg)
Imcyse to present positive results in EAE model of multiple sclerosis at ECTRIMS 2019
![Domain Therapeutics reaches two milestones in multi-target research collaboration with Boehringer Ingelheim](https://ala.associates/wp-content/uploads/2022/04/30-sept-mec.png)
Domain Therapeutics invests in Ermium Therapeutics to develop first-in-class CXCR4 candidate for autoimmune diseases
![Yposkesi’s viral vectors used in gene therapy-based clinical trial](https://ala.associates/wp-content/uploads/2022/04/Building-Yposkesi-362x250-1.jpg)